GENEREX BIOTECHNOLOGY CORP
GNBT
GNBT was delisted on the 20th of October, 2010.
1 hedge funds and large institutions have $0 invested in GENEREX BIOTECHNOLOGY CORP in 2015 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less capital invested
Capital invested by funds: $598 → $0 (-$598)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$598 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$598 | -54,400 | Closed |
|
GNBT Hedge Fund Activity: Q1 2015 in Review
1 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in GENEREX BIOTECHNOLOGY CORP (GNBT) for Q1 2015, worth a combined $0 — down 100% from $598 a quarter earlier.
Fund positioning in GNBT was balanced in Q1 2015: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Janney Montgomery Scott, exiting entirely with an estimated $598 sold.
- 1 institutional investor held GENEREX BIOTECHNOLOGY CORP (GNBT) as of Q1 2015, unchanged from Q4 2014.
- Funds reported $0 of GENEREX BIOTECHNOLOGY CORP stock for Q1 2015, down 100% quarter-over-quarter.
- 1 fund opened new GENEREX BIOTECHNOLOGY CORP positions in Q1 2015 and 1 closed out, a net change of 0 holders.
- The largest GENEREX BIOTECHNOLOGY CORP seller in Q1 2015 was Janney Montgomery Scott, an estimated $598 sold.
Based on aggregated 13F filings for Q1 2015.